Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Interest & Investment Income (2020 - 2023)

Cullinan Therapeutics has reported Interest & Investment Income over the past 4 years, most recently at $5.9 million for Q4 2023.

  • Quarterly results put Interest & Investment Income at $5.9 million for Q4 2023, up 75.89% from a year ago — trailing twelve months through Dec 2023 was $21.6 million (up 227.14% YoY), and the annual figure for FY2025 was $22.2 million, down 25.11%.
  • Interest & Investment Income for Q4 2023 was $5.9 million at Cullinan Therapeutics, up from $5.9 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for CGEM hit a ceiling of $5.9 million in Q4 2023 and a floor of $49000.0 in Q1 2021.
  • Median Interest & Investment Income over the past 4 years was $312000.0 (2020), compared with a mean of $1.9 million.
  • Biggest five-year swings in Interest & Investment Income: plummeted 87.04% in 2021 and later skyrocketed 2355.47% in 2022.
  • Cullinan Therapeutics' Interest & Investment Income stood at $79000.0 in 2020, then surged by 73.42% to $137000.0 in 2021, then skyrocketed by 2355.47% to $3.4 million in 2022, then skyrocketed by 75.89% to $5.9 million in 2023.
  • The last three reported values for Interest & Investment Income were $5.9 million (Q4 2023), $5.9 million (Q3 2023), and $5.3 million (Q2 2023) per Business Quant data.